Overview of the Market:
The Global Psoriasis Drugs Market is expected to reach USD 12.45 billion by 2023 from USD 8.75 billion in 2018, growing at a CAGR of 7.30 % during the forecast period 2018-2023. Psoriasis is noncommunicable, inflammatory skin condition that alter the life cycle of skin cells by speeding up the cell building process on the surface of the skin. Rapid development of cells produces thick, silver scales, and makes the skin red, dry, flaky, and itchy. The various types of psoriasis are vulgaris, guttate, inverse, pustular, palmoplantar, erythrodermic, nail, and scalp psoriasis. According to International Federation of Psoriasis Association, approximately 3% or more than 125 million of the world’s population are living with psoriasis. Additionally, approximately 10% of the population have severe form of psoriasis, among diagnosed population, and 90% of the people fall under moderate to mild category of psoriasis. Currently, no permanent cure is available for the disease, however preventative measures can be adopted to slow down the growth of cells on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through topical and systemic process. These medications when administered, either by applying on the skin, or consumed orally, or through injections, specifically block parts of immune system process by targeting Tumour Necrosis Factor, Phosphodiesterase Type 4, Interleukin, among others.

The growth of Psoriasis Drugs market is majorly driven by factors such as rising healthcare expenditure, boost in psoriasis Research and Development investment, introduction of novel and more efficient drug, and increasing demand of psoriasis medicines in emerging economies. Additionally, psoriasis requires long term treatment as it can reoccur after the first line treatment, thereby increasing sales revenue. Also, with the availability of better diagnostic devices will result in building confidence in people, thereby resulting in increasing treatment-seeking population. People seeking treatment for Psoriasis are also showing interest in combination therapies. A combination therapy of Topical and Systemic (Alefacept, etanercept, and others taken with methotrexate) have shown better results in patient. Expected entry of late-stage pipeline products (Xeljanz and the biosimilar adalimumab by Pfizer) are anticipated to accelerate the growth of the product. The key restraints of the market are high cost involved in drug development, patent expiry of brand name drugs, increasing availability of generic products, side effects from the systemic and biologics medication (high blood pressure, liver and kidney damage, infection, and cancer of the lymph nodes), lack of access to healthcare, health insurance issues, and low efficacy of the product.

The global Psoriasis Drugs Market is segmented on the basis of Drug Type, Route of Administration, and Target. Based on Drug Type, the market is classified into Pharmaceuticals and Biopharmaceuticals. On the basis of Route of Administration, the market is classified into Topical and Systemic (Oral, Intravenous, and Others). On the basis of Target, the market is classified into Tumour Necrosis Factor (TNF), Phosphodiesterase Type 4 (PDE4), Interleukin, and Others

Geographical Analysis:
The market has also been geographically segmented into North America, Europe, Asia-Pacific and the Middle-East and Africa. North America is expected to command the major market share of 41% in 2016 followed by Europe. Asia Pacific is anticipated to be the fastest growing region for the product with a CAGR of 8.24% during the forecast period 2016-2021.

Global, Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail

Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development

A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment

Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions

Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market